Orelabrutinib
| Clinical data | |
|---|---|
| Trade names | 宜诺凯 (China), Hibruka (Singapore) |
| Other names | ICP-022; ICP022 |
| Drug class | Bruton's tyrosine kinase inhibitor |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C26H25N3O3 |
| Molar mass | 427.504 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Orelabrutinib is a small molecule inhibitor of Bruton's tyrosine kinase used for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and marginal zone lymphoma.[1][2][3]
In China, it is approved for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), who have received at least one treatment in the past.[1]
In Singapore, it is approved for adult patients with relapsed or refractory marginal zone lymphoma (R/R MZL).[3]
Orelabrutinib is an inhibitor of Bruton's tyrosine kinase, thus being a BTK inhibitor.[2]
Society and culture
[edit]Legal status
[edit]Orelabrutinib was approved for medical use in China in December 2020.[1]
Orelabrutinib was approved for medical use in Singapore in September 2025.[3]
Names
[edit]Orelabrutinib is the international nonproprietary name.
Orelabrutinib is sold under the brand names 宜诺凯 in China, and Hibruka in Singapore.[1][3]
References
[edit]- 1 2 3 4 Dhillon S (March 2021). "Orelabrutinib: First Approval". Drugs. 81 (4): 503–507. doi:10.1007/s40265-021-01482-5. PMID 33704654.
- 1 2 Deng LJ, Zhou KS, Liu LH, Zhang MZ, Li ZM, Ji CY, et al. (August 2023). "Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study". Blood Advances. 7 (16): 4349–4357. doi:10.1182/bloodadvances.2022009168. PMC 10432605. PMID 37078706.
- 1 2 3 4 "InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore | INNOCARE". www.innocarepharma.com. Archived from the original on 2026-06-16. Retrieved 2026-10-22.